Literature DB >> 33520806

Mechanistic dissection of diabetic retinopathy using the protein-metabolite interactome.

Ambrose Teru Patrick1, Weilue He2, Joshua Madu1, Srinivas R Sripathi3, Seulggie Choi4, Kook Lee4, Faith Pwaniyibo Samson1, Folami L Powell5, Manuela Bartoli6, Donghyun Jee4, Diana R Gutsaeva6, Wan Jin Jahng1.   

Abstract

PURPOSE: The current study aims to determine the molecular mechanisms of diabetic retinopathy (DR) using the protein-protein interactome and metabolome map. We examined the protein network of novel biomarkers of DR for direct (physical) and indirect (functional) interactions using clinical target proteins in different models.
METHODS: We used proteomic tools including 2-dimensional gel electrophoresis, mass spectrometry analysis, and database search for biomarker identification using in vivo murine and human model of diabetic retinopathy and in vitro model of oxidative stress. For the protein interactome and metabolome mapping, various bioinformatic tools that include STRING and OmicsNet were used.
RESULTS: We uncovered new diabetic biomarkers including prohibitin (PHB), dynamin 1, microtubule-actin crosslinking factor 1, Toll-like receptor (TLR 7), complement activation, as well as hypothetical proteins that include a disintegrin and metalloproteinase (ADAM18), vimentin III, and calcium-binding C2 domain-containing phospholipid-binding switch (CAC2PBS) using a proteomic approach. Proteome networks of protein interactions with diabetic biomarkers were established using known DR-related proteome data. DR metabolites were interconnected to establish the metabolome map. Our results showed that mitochondrial protein interactions were changed during hyperglycemic conditions in the streptozotocin-treated murine model and diabetic human tissue.
CONCLUSIONS: Our interactome mapping suggests that mitochondrial dysfunction could be tightly linked to various phases of DR pathogenesis including altered visual cycle, cytoskeletal remodeling, altered lipid concentration, inflammation, PHB depletion, tubulin phosphorylation, and altered energy metabolism. The protein-metabolite interactions in the current network demonstrate the etiology of retinal degeneration and suggest the potential therapeutic approach to treat DR. © Springer Nature Switzerland AG 2020.

Entities:  

Keywords:  ADAM18; CAC2PBS; Diabetic retinopathy; Interactome; Metabolome; Mitochondria; Prohibitin; Proteomics; Tubulin

Year:  2020        PMID: 33520806      PMCID: PMC7843730          DOI: 10.1007/s40200-020-00570-9

Source DB:  PubMed          Journal:  J Diabetes Metab Disord        ISSN: 2251-6581


  109 in total

Review 1.  Inflammation in diabetic retinopathy.

Authors:  Johnny Tang; Timothy S Kern
Journal:  Prog Retin Eye Res       Date:  2011-05-25       Impact factor: 21.198

2.  Thioredoxin is implicated in the anti‑apoptotic effects of grape seed proanthocyanidin extract during hyperglycemia.

Authors:  Xiang Ren; Heyuan Lu; Nina Wang; Chenghong Zhang; Yunpeng Ji; Shiqi Cui; Yichen Dong; Kaiyuan Yang; Mengyi Du; Fengsheng Diao; Li Kong
Journal:  Mol Med Rep       Date:  2017-09-18       Impact factor: 2.952

Review 3.  From oxygen to erythropoietin: relevance of hypoxia for retinal development, health and disease.

Authors:  Christian Caprara; Christian Grimm
Journal:  Prog Retin Eye Res       Date:  2011-11-16       Impact factor: 21.198

4.  Determination of diabetic retinopathy prevalence and associated risk factors in Chinese diabetic and pre-diabetic subjects: Shanghai diabetic complications study.

Authors:  Can Pang; Lili Jia; Sunfang Jiang; Wei Liu; Xuhong Hou; Yuhua Zuo; Huilin Gu; Yuqian Bao; Qiang Wu; Kunsan Xiang; Xin Gao; Weiping Jia
Journal:  Diabetes Metab Res Rev       Date:  2012-03       Impact factor: 4.876

5.  Role of matrix metalloproteinase-9 in the development of diabetic retinopathy and its regulation by H-Ras.

Authors:  Renu A Kowluru
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-03-10       Impact factor: 4.799

6.  Hyperglycemia attenuates acute permeability response to advanced glycation end products in retinal microvasculature.

Authors:  C M Warboys; P A Fraser
Journal:  Microvasc Res       Date:  2010-03-17       Impact factor: 3.514

7.  Methylglyoxal induces retinopathy-type lesions in the absence of hyperglycemia: studies in a rat model.

Authors:  Andrea Schlotterer; Matthias Kolibabka; Jihong Lin; Kübra Acunman; Nadine Dietrich; Carsten Sticht; Thomas Fleming; Peter Nawroth; Hans-Peter Hammes
Journal:  FASEB J       Date:  2018-11-28       Impact factor: 5.191

8.  Intravitreal injection of erythropoietin protects both retinal vascular and neuronal cells in early diabetes.

Authors:  Jingfa Zhang; Yalan Wu; Ying Jin; Fei Ji; Stephen H Sinclair; Yan Luo; Guoxu Xu; Luo Lu; Wei Dai; Myron Yanoff; Weiye Li; Guo-Tong Xu
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-02       Impact factor: 4.799

9.  Angiotensin AT1 receptor antagonism ameliorates murine retinal proteome changes induced by diabetes.

Authors:  Ben-Bo Gao; Joanna A Phipps; Dahlia Bursell; Allen C Clermont; Edward P Feener
Journal:  J Proteome Res       Date:  2009-12       Impact factor: 4.466

10.  Development of Diagnostic Biomarkers for Detecting Diabetic Retinopathy at Early Stages Using Quantitative Proteomics.

Authors:  Jonghwa Jin; Hophil Min; Sang Jin Kim; Sohee Oh; Kyunggon Kim; Hyeong Gon Yu; Taesung Park; Youngsoo Kim
Journal:  J Diabetes Res       Date:  2015-11-09       Impact factor: 4.011

View more
  3 in total

Review 1.  Contribution of Müller Cells in the Diabetic Retinopathy Development: Focus on Oxidative Stress and Inflammation.

Authors:  Raul Carpi-Santos; Ricardo A de Melo Reis; Flávia Carvalho Alcantara Gomes; Karin C Calaza
Journal:  Antioxidants (Basel)       Date:  2022-03-23

Review 2.  Metabolism and Vascular Retinopathies: Current Perspectives and Future Directions.

Authors:  Charandeep Singh
Journal:  Diagnostics (Basel)       Date:  2022-04-05

3.  Prohibitin 1 Regulates Inflammatory Mediators and Reactive Oxygen Species in Retinal Endothelial Cells.

Authors:  Li Liu; Youde Jiang; Jena J Steinle
Journal:  J Clin Med       Date:  2022-03-30       Impact factor: 4.964

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.